Explore

Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition
Trendline Trendline
Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions

Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions

Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions
Trendline Trendline
Gilead Sciences Shifts Focus to Integration After Series of Acquisitions

Gilead Sciences Shifts Focus to Integration After Series of Acquisitions

Gilead Sciences Shifts Focus to Integration After Series of Acquisitions
Trendline Trendline
Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition
Trendline Trendline
Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates

Webinar Explores Analytical Strategies for Complex Antibody-Drug Conjugates
Trendline Trendline
Citeline Reports First Decline in Pharma Pipeline Since 1990s, Impacting Drug Development

Citeline Reports First Decline in Pharma Pipeline Since 1990s, Impacting Drug Development

Citeline Reports First Decline in Pharma Pipeline Since 1990s, Impacting Drug Development
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026
Trendline Trendline
Pharmaceutical R Pipeline Experiences First Decline in Decades, Citeline Reports

Pharmaceutical R Pipeline Experiences First Decline in Decades, Citeline Reports

Pharmaceutical R Pipeline Experiences First Decline in Decades, Citeline Reports
Trendline Trendline
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors